The immuno-oncology drug Keytruda has taken the lead in the domestic market for the 4th consecutive year. Its quarterly sales exceeded KRW 100 billion for the first time in the domestic market after being expanded reimbursement to the first line. The gap with the runner-up had more than doubled, reinforcing Keytruda’s leadership in the market.

According to the market research institution IQVIA on the 21st, MSD’s Keytruda topped the list of drugs sold in Korea last year with sales of KRW 398.7 billion. The drug had continued to show high growth, rising 66.4% from the previous year. This is the fourth consecutive year that Keytruda has kept the lead, having first topped the list in 2020 with sales of KRW 1